AKT1 and Alzheimer disease: Moreover, Del Cerro et al. [64] demonstrated that the CB2R agonist PGN33 decreased the viability of lymphoblasts from late-onset AD patients and mitigated Aβ-induced neuroblastoma cell death, implicating impedance of the Ca2+/calmodulin-dependent activation of PI3K/Akt signaling pathway.